{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T19:24:44.462165+00:00","company":{"ticker":"HOTH","cik":1711786,"company_name":"Hoth Therapeutics, Inc."},"pagination":{"limit":100,"returned":5,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"governance_change","fact_key":"7a3d107d313c2a32e61e1b7b2db290e867a9c85a","cik":1711786,"ticker":"HOTH","company_name":"Hoth Therapeutics, Inc.","filed_at":"2026-05-27T12:33:47+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-05-26","item_codes_triggered":["5.03"],"summary_text":"Hoth Therapeutics, Inc. filed a Certificate of Amendment to change its name to 'Rocket One Inc.' effective May 26, 2026, and will start trading under the symbol 'RKTO' on May 28, 2026."},"claim":"Hoth Therapeutics, Inc.: Hoth Therapeutics, Inc. filed a Certificate of Amendment to change its name to 'Rocket One Inc.' effective May 26, 2026, and will start trading under the symbol 'RKTO' on May 28, 2026 (effective 2026-05-26).","evidence_excerpt":"On May 20, 2026, Rocket One Inc. (formerly, Hoth Therapeutics, Inc.) (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation, as amended (the “Charter Amendment”), with the Secretary of State of the State of Nevada to change the name of the Company from “Hoth Therapeutics, Inc.” to “Rocket One Inc.” effective as of May 26, 2026 (the “Name Change”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-26-061252","anchor_url":"https://secwatch.observer/filing/0001213900-26-061252#claim-7a3d107d313c2a32e61e1b7b2db290e867a9c85a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1711786/000121390026061252/0001213900-26-061252-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"70e0080446dcf0ddc35a2f4023b6b0dea07386ae","cik":1711786,"ticker":"HOTH","company_name":"Hoth Therapeutics, Inc.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2026-10-27","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2026-04-30","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Hoth Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"April 30, 2026, Hoth\nTherapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that\nit is not in compliance with the minimum bid price requirements set forth i","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-26-051728","anchor_url":"https://secwatch.observer/filing/0001213900-26-051728#claim-70e0080446dcf0ddc35a2f4023b6b0dea07386ae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1711786/000121390026051728/0001213900-26-051728-index.htm"},{"fact_type":"material_agreement","fact_key":"e9c0295a9e2c34ecce9ccb08901268aa47a4b662","cik":1711786,"ticker":"HOTH","company_name":"Hoth Therapeutics, Inc.","filed_at":"2026-04-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain institutional investors","effective_date":"2026-04-01","item_codes_triggered":["1.01"],"value_text":"Company agreed to sell 2,857,144 shares of common stock at $0.70 per share; gross proceeds approxima"},"claim":"Hoth Therapeutics, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at Company agreed to sell 2,857,144 shares of common stock at $0.70 per share; gross proceeds approxima (effective 2026-04-01).","evidence_excerpt":"On April 1, 2026, Hoth Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell to such investors 2,857,144 shares (the “Shares”) of common stock of the Company (the “Common Stock”), at a purchase price of $0.70 per share of Common Stock (the “Offering”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-039363","anchor_url":"https://secwatch.observer/filing/0001213900-26-039363#claim-e9c0295a9e2c34ecce9ccb08901268aa47a4b662","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1711786/000121390026039363/0001213900-26-039363-index.htm"},{"fact_type":"executive_change","fact_key":"4a6cbd7bab","cik":1711786,"ticker":"HOTH","company_name":"Hoth Therapeutics, Inc.","filed_at":"2025-04-15T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-04-15","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Graig Springer resigned as Director at Hoth Therapeutics, Inc..","evidence_excerpt":"On April 9, 2025, Graig Springer informed Hoth Therapeutics, Inc. (the “Company”) that he will be resigning from the Company’s Board of Directors (the “Board”) as well as the Company’s audit committee, compensation committee and nominating and corporate governance committee effective as of April 15, 2025.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-25-031763","anchor_url":"https://secwatch.observer/filing/0001213900-25-031763#claim-4a6cbd7bab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1711786/000121390025031763/0001213900-25-031763-index.htm"},{"fact_type":"material_agreement","fact_key":"bcdbb3ba997df9172c0e175a831505a224c1bfea","cik":1711786,"ticker":"HOTH","company_name":"Hoth Therapeutics, Inc.","filed_at":"2024-03-28T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Inducement Letter","agreement_type":"equity_purchase","counterparty":"a certain holder of existing warrants","effective_date":"2024-03-27","item_codes_triggered":["1.01"],"value_text":"aggregate gross proceeds of approximately $4.2 million"},"claim":"Hoth Therapeutics, Inc. entered into Inducement Letter with a certain holder of existing warrants valued at aggregate gross proceeds of approximately $4.2 million (effective 2024-03-27).","evidence_excerpt":"On March 27, 2024, Hoth Therapeutics, Inc., a Nevada corporation (the “ Company ”), entered into an inducement offer letter agreement (the “ Inducement Letter ”) with a certain holder (the “ Holder ”) of existing warrants (the “ Existing Warrants ”) to purchase shares of common stock of the Company.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-026868","anchor_url":"https://secwatch.observer/filing/0001213900-24-026868#claim-bcdbb3ba997df9172c0e175a831505a224c1bfea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1711786/000121390024026868/0001213900-24-026868-index.htm"}]}